15. Conclusion and future directions for Mpox research and
control measures.
Indeed, the Mpox virus has long been a neglected zoonotic disease with
the potential to spread and/or be used as a bioweapon. There are now no
traditional guidelines for clinical care, medications, or vaccinations
although the condition was originally diagnosed in 1958 and first
recorded in a human in 197078. Limited research on the
human immune response to Monkeypox virus (MPXV) infection remains
unanswered. Understanding immune defenses and the potential for mucosal
protection resulting from smallpox immunization or MPXV infection is
essential. Investigating tissue-resident memory T cells and IgA in
MPXV-related respiratory complications is essential. Factors like
behavior, geography, diet, medical history, immunological factors, and
genetics may also impact MPXV susceptibility and immunity. The virus can
spread globally and has the potential to expand beyond Africa. Effective
management strategies, such as ring-vaccination and pre-exposure
vaccination, are needed to combat the outbreak. Increased surveillance
efforts, vaccination availability, and antiviral medications can help
mitigate the threat of MPXV. Also, it is a clear call to action for
public health authorities to assume responsibility for informing
specialists in the field of their results and being open and truthful
with the general public. Recent outbreaks around the globe have
highlighted the significance of rigorous and ongoing surveillance as
well as the creation of novel preventative and therapeutic strategies.
To stop rising transmission rates or virulence, appropriate and
effective medicines as well as active monitoring activities are urgently
needed78. Considering At least in endemic regions and
possibly globally, the Mpox virus is the most major orthopoxvirus in
humans. It takes a lot of effort to prevent Mpox, which is no longer a
rare condition. The human Mpox virus should be monitored and controlled
using the insights learnt from the Covid-19 epidemic.